Allergan pulled up by FDA

Article

The FDA has sent Allergan a warning letter relating to misleading information printed in a professional journal advertisement for its ophthalmic solution, Acular LS.

The FDA has sent Allergan a warning letter relating to misleading information printed in a professional journal advertisement for its ophthalmic solution, Acular LS.

The FDA remonstrated Allergan for printing information that broadens the product's indication, presents unsubstantiated superiority claims and omits important risk information for Acular LS.

Acular LS, according to the FDA approved product labelling, is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

Related Videos
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Dr Ali Erginay discusses his EURETINA presentation
© 2023 MJH Life Sciences

All rights reserved.